Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Brimonidine tartrate ophthalmic solution, 0.2%, Brimonidine tartrate 0.2% ophthalmic solution, Brimonidine 0.2%, Brimonidine Tartrate Ophthalmic Solution, Brimonidine
Brimonidine, 0.2% · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Brimonidine Tartrate Ophthalmic Solution | DRUG | - |
* Patients of any race * two (2) years of age or older * of either sex * diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)or ocular hypertension
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Brimonidine, 0.2% is an ophthalmic solution used to treat open-angle glaucoma. It is a small molecule alpha-2 adrenergic receptor agonist developed by Alcon Inc. (ticker: ALC). The drug is currently in Phase 3 clinical development.
Brimonidine, 0.2% targets the alpha-2 adrenergic receptors ADRA2A, ADRA2C, and ADRA2B. It acts as an agonist at these receptors. This mechanism is relevant to its use in ophthalmology for lowering intraocular pressure in open-angle glaucoma.
Brimonidine, 0.2% is developed by Alcon Inc., which trades under the ticker ALC. Alcon is a pharmaceutical company focused on eye care products.
Brimonidine, 0.2% is in Phase 3 clinical development. It is investigational and has not been approved by the FDA for any indication. The development program includes one completed Phase 3 trial.
Brimonidine, 0.2% has been studied in one completed Phase 3 trial, NCT00061529. The trial was titled 'A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension' and was conducted in the United States. It was randomized and double-blind.
Yes, brimonidine, 0.2% is also known as brimonidine tartrate ophthalmic solution, 0.2%, brimonidine tartrate 0.2% ophthalmic solution, brimonidine 0.2%, brimonidine 2 mg/mL eye drops, solution, and brimonidine/mL eye. These names refer to the same product.